Kubota Akinobu, Bandoh Nobuyuki, Goto Takashi, Kono Michihisa, Sato Ryosuke, Suzuki Shiori, Sakaue Shota, Takeda Ryuhei, Hayashi Shuto, Hayashi Misaki, Araki Daisuke, Baba Shogo, Kato Yasutaka, Takahara Miki, Nishihara Hiroshi, Kamada Hajime
Department of Otolaryngology-Head and Neck Surgery, Hokuto Hospital, Obihiro, Hokkaido 080-0833, Japan.
Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan.
Mol Clin Oncol. 2025 Jul 17;23(4):87. doi: 10.3892/mco.2025.2882. eCollection 2025 Oct.
The aim of this study was to assess clinical features, outcomes and survival in patients with laryngeal squamous cell carcinoma (LSCC) and to associate mutations in cancer-related genes with clinical outcomes. A total of 88 patients with LSCC who underwent curative treatment between April 2008 and May 2024 at Hokuto Hospital (Obihiro, Japan) were included. Mutations in targeted regions of 160 cancer-related genes were analyzed using next-generation sequencing (NGS). LSCC was of glottic type in 65 patients (74%) and supraglottic type in 23 patients (26%). As initial treatment, laryngomicrosurgery, radiotherapy (RT) alone, RT with transoral administration of S-1, concurrent chemoradiotherapy with cisplatin, and total laryngectomy were performed in 6 (7%), 48 (55%), 13 (15%), 8 (9%), and 13 (15%) patients, respectively. Of the 88 patients studied, 25 (28%) died of various causes, including LSCC in 6 (7%), carcinoma other than LSCC in 11 (13%), and other causes in 8 (9%). The 5-year survival rates among all 88 patients with LSCC were 78.7% for overall survival (OS), 91.4% for disease-specific survival (DSS), 77.3% for relapse-free survival (RFS) and 67.5% for laryngectomy-free survival (LFS). OS, DSS, RFS and LFS in patients with early stage LSCC were similar to rates reported in other studies. Actionable mutations were detected in 21 (88%) of 24 patients who underwent NGS-based cancer panel testing. mutations were detected in 18 (75%), in 5 (21%), in 3 (13%) and in 2 (8%) of these 24 patients. Multivariate Cox proportional hazard analysis revealed that mutation was an independent prognostic factor for RFS (P=0.011). Overall, detection of mutations in cancer-related genes could enhance understanding of clinical outcomes in LSCC.
本研究的目的是评估喉鳞状细胞癌（LSCC）患者的临床特征、结局和生存率，并将癌症相关基因的突变与临床结局相关联。纳入了2008年4月至2024年5月期间在北斗医院（日本带广）接受根治性治疗的88例LSCC患者。使用下一代测序（NGS）分析了160个癌症相关基因靶向区域的突变。65例患者（74%）的LSCC为声门型，23例患者（26%）为声门上型。作为初始治疗，6例（7%）患者接受了喉显微手术，48例（55%）患者接受了单纯放疗（RT），13例（15%）患者接受了RT联合经口给予S-1，8例（9%）患者接受了顺铂同步放化疗，13例（15%）患者接受了全喉切除术。在研究的88例患者中，25例（28%）死于各种原因，包括6例（7%）死于LSCC，11例（13%）死于LSCC以外的癌症，8例（9%）死于其他原因。88例LSCC患者的5年总生存率（OS）为78.7%，疾病特异性生存率（DSS）为91.4%，无复发生存率（RFS）为77.3%，无喉切除生存率（LFS）为67.5%。早期LSCC患者的OS、DSS、RFS和LFS与其他研究报道的比率相似。在24例接受基于NGS的癌症基因检测的患者中，21例（88%）检测到可操作的突变。在这24例患者中，18例（75%）检测到 突变，5例（21%）检测到 突变，3例（13%）检测到 突变，2例（8%）检测到 突变。多因素Cox比例风险分析显示， 突变是RFS的独立预后因素（P=0.011）。总体而言，检测癌症相关基因的突变可以增强对LSCC临床结局的理解。
